Target Price | $7.22 |
Price | $1.44 |
Potential |
401.10%
register free of charge
|
Number of Estimates | 6 |
6 Analysts have issued a price target Innate Pharma - ADR 2025 .
The average Innate Pharma - ADR target price is $7.22.
This is
401.10%
register free of charge
$11.50
698.61%
register free of charge
$2.48
72.50%
register free of charge
|
|
A rating was issued by 6 analysts: 5 Analysts recommend Innate Pharma - ADR to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Innate Pharma - ADR stock has an average upside potential 2025 of
401.10%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 56.11 | 47.97 |
7.68% | 14.51% | |
EBITDA Margin | -33.36% | -17.61% |
18.11% | 47.22% | |
Net Margin | -14.43% | 39.32% |
87.94% | 372.54% |
3 Analysts have issued a sales forecast Innate Pharma - ADR 2024 . The average Innate Pharma - ADR sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Innate Pharma - ADR EBITDA forecast 2024. The average Innate Pharma - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
1 Analyst has issued a net profit forecast Innate Pharma - ADR 2024 . The average Innate Pharma - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.10 | 0.23 |
87.01% | 330.00% | |
P/E | 6.18 | |
EV/Sales | 1.17 |
1 Analysts have issued a Innate Pharma - ADR forecast for earnings per share. The average Innate Pharma - ADR <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Innate Pharma - ADR stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Innate Pharma - ADR...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.